NCT07570654PHASE2, PHASE3Recruiting
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways
Start Date
9/1/2026
Completion Date
9/1/2029
Summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* 18 years or older
* Diagnosed with PTSD at least 6 months ago
Exclusion Criteria:
\- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions
Interventions
DRUG
COMP360 psilocybin
Conditions
PTSD - Post Traumatic Stress DisorderPTSDPTSD SymptomsPTSD, Post Traumatic Stress Disorder
Locations
FL
Miami, Florida 33125
United States
FL
Orlando, Florida 32801
United States
IL
Chicago, Illinois 60612
United States
MN
Eden Prairie, Minnesota 55347
United States
NE
Lincoln, Nebraska 68526
United States
NV
Las Vegas, Nevada 89119
United States
NY
New York, New York 10025
United States
BC
North Vancouver, British Columbia V7P2T4
Canada